All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
ASH 2020 highlights for myelofibrosis
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What is the long-term benefit of momelotinib treatment in relapsed/refractory myelofibrosis (MF)?
JAK inhibition has made a significant impact on patients with MF. Momelotinib is a JAK1/2 and ACVR1 inhibitor, which improves anemia and most importantly survival. Mesa also mentions the JAK inhibitor pipeline and which inhibitors will soon become available, offering more treatment options.
ASH 2020 highlights for myelofibrosis
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox